Key clinical point: Cluster of differentiation 33 (CD33) single-nucleotide polymorphism (SNP) rs12459419 predicts the rate of relapse in patients with nucleophosmin1 ( NPM1)-mutated acute myeloid leukemia (AML) treated with gemtuzumab ozogamicin (GO).
Major finding: Complete remission, event-free survival, and cumulative incidence of death were not significantly different between genotypes in the treatment arms. However, patients with c.41 C/C genotype for rs12459419 in the GO vs. standard arm showed significant improvement in relapse-free survival ( P = .03) and cumulative incidence of relapse ( P = .023).
Study details: Findings are from the phase 3 AMLSG 09-09 trial including 588 adult patients with NPM1-mutated AML who were eligible for intensive therapy. Patients were randomly allocated to receive 2 cycles of induction chemotherapy with (n=273) or without (n=272) GO.
Disclosures: This work was supported by grants from the Deutsche José Carreras Leukämie-Stiftung e.V., German Federal Ministry of Education and Research, and Deutsche Forschungsgemeinschaft. The authors declared no conflicts of interest.
Source: Teich K et al. Haematologica. 2021 May 27. doi: 10.3324/haematol.2021.278894 .